Knockdown of Ubiquitin-Specific Protease 53 Enhances the Radiosensitivity of Human Cervical Squamous Cell Carcinoma by Regulating DNA Damage-Binding Protein 2.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
Historique:
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 5 1 2021
Statut: ppublish

Résumé

Cervical cancer ranks fourth in incidence and mortality among women. Ubiquitin-specific protein 53 binds to damage-specific DNA binding protein 2 and affects the biological properties of colon cancer. Damage-specific DNA binding protein is involved in nucleotide excision repair, which can repair DNA damage. However, the mechanism by which ubiquitin-specific protein 53 regulates the radiosensitivity of cervical cancer through damage-specific DNA binding protein remains unclear. Tissue samples from 40 patients with cervical squamous cell carcinoma who received radiotherapy were examined by immunohistochemistry to detect the expression of ubiquitin-specific protein 53, and clinical data were collected for statistical analysis. The cell cycle was detected by flow cytometry in Siha cells transfected with Si-USP53 and exposed to 8 Gy irradiation. Cell viability was determined by the CCK8 method in cells transfected with Si-USP53 and exposed to 0, 2, 4, 6, 8, or 10 Gy. The expression of damage-specific DNA binding protein, cyclin-dependent kinase 1, and cell cycle checkpoint kinase 2 was detected in cells transfected with Si-USP53. The expression of ubiquitin-specific protein 53 in the tissues of patients with cervical squamous cell carcinoma was correlated with the sensitivity to radiotherapy. Knockdown of ubiquitin-specific protein 53 in Siha cells downregulated damage-specific DNA binding protein and caused G2/M cell cycle arrest and decreased the survival rate of cells in response to radiation. Ubiquitin-specific protein 53-induced cell cycle arrest and affected the radiotherapy sensitivity of tumors through damage-specific DNA binding protein.

Sections du résumé

BACKGROUND
Cervical cancer ranks fourth in incidence and mortality among women. Ubiquitin-specific protein 53 binds to damage-specific DNA binding protein 2 and affects the biological properties of colon cancer. Damage-specific DNA binding protein is involved in nucleotide excision repair, which can repair DNA damage. However, the mechanism by which ubiquitin-specific protein 53 regulates the radiosensitivity of cervical cancer through damage-specific DNA binding protein remains unclear.
METHODS
Tissue samples from 40 patients with cervical squamous cell carcinoma who received radiotherapy were examined by immunohistochemistry to detect the expression of ubiquitin-specific protein 53, and clinical data were collected for statistical analysis. The cell cycle was detected by flow cytometry in Siha cells transfected with Si-USP53 and exposed to 8 Gy irradiation. Cell viability was determined by the CCK8 method in cells transfected with Si-USP53 and exposed to 0, 2, 4, 6, 8, or 10 Gy. The expression of damage-specific DNA binding protein, cyclin-dependent kinase 1, and cell cycle checkpoint kinase 2 was detected in cells transfected with Si-USP53.
RESULTS
The expression of ubiquitin-specific protein 53 in the tissues of patients with cervical squamous cell carcinoma was correlated with the sensitivity to radiotherapy. Knockdown of ubiquitin-specific protein 53 in Siha cells downregulated damage-specific DNA binding protein and caused G2/M cell cycle arrest and decreased the survival rate of cells in response to radiation.
CONCLUSION
Ubiquitin-specific protein 53-induced cell cycle arrest and affected the radiotherapy sensitivity of tumors through damage-specific DNA binding protein.

Identifiants

pubmed: 32508265
doi: 10.1177/1533033820929792
pmc: PMC7281878
doi:

Substances chimiques

Biomarkers, Tumor 0
DDB2 protein, human 0
DNA-Binding Proteins 0
USP53 protein, human EC 3.4.19.12
Ubiquitin-Specific Proteases EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533033820929792

Commentaires et corrections

Type : ErratumIn

Références

DNA Repair (Amst). 2016 Jun;42:63-71
pubmed: 27156098
Oncol Res Treat. 2016;39(9):516-20
pubmed: 27614991
Cell Cycle. 2012 Dec 1;11(23):4378-84
pubmed: 23159851
Eur J Pharmacol. 2016 Jan 15;771:77-83
pubmed: 26688569
Oncogene. 2012 May 10;31(19):2373-88
pubmed: 21996736
Dis Esophagus. 2017 Jun 1;30(6):1-7
pubmed: 28475750
Radiat Oncol. 2015 Nov 14;10:227
pubmed: 26572130
EMBO Rep. 2017 Aug;18(8):1318-1330
pubmed: 28623188
J Neurosci. 2015 Nov 25;35(47):15582-98
pubmed: 26609154
Int J Cancer. 2010 Aug 15;127(4):977-88
pubmed: 20013802
Pathol Oncol Res. 2017 Apr;23(2):323-328
pubmed: 27585443
Cancer Cell Int. 2018 May 1;18:64
pubmed: 29743814
Med Sci Monit. 2015 May 05;21:1276-87
pubmed: 25940978
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Cell Death Dis. 2017 Mar 23;8(3):e2693
pubmed: 28333152
Cell Cycle. 2009 Dec 15;8(24):4067-71
pubmed: 19923893
Radiat Environ Biophys. 2017 Mar;56(1):89-98
pubmed: 28184999
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cancer Res. 2017 Apr;15(4):418-428
pubmed: 28087741
Tumour Biol. 2016 Oct;37(10):14183-14191
pubmed: 27553023
Biochem Biophys Res Commun. 2004 Jan 30;314(1):54-62
pubmed: 14715245

Auteurs

Qifen Zhou (Q)

Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.

Xiongbo Yao (X)

The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.

Chunlin Wu (C)

Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.

Shaohua Chen (S)

Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.

Dage Fan (D)

Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH